Veeda Lifesciences Partners with Mango Sciences to Enhance Clinical Trials
Veeda Lifesciences, a leading contract research organization (CRO), has taken a significant step forward by investing in Mango Sciences, a data and AI technology company based in Boston. This strategic collaboration is set to revolutionize clinical trial services by integrating advanced AI capabilities, enabling a more efficient, speedy, and quality-driven approach to clinical research.
Transformative AI in Clinical Trials
Through this partnership, Veeda aims to harness the power of Mango Sciences' Querent™ platform. By leveraging this innovative technology, Veeda will automate patient identification with a high degree of accuracy, ultimately enhancing its ability to connect with global patient populations. This technology will not only boost operational efficiency but also broaden access to diverse patient demographics across various regions.
Addressing Diversity in Clinical Trials
The journey towards automation and digital transformation is particularly important in clinical trials. As Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Clinical Research Limited, emphasized, this partnership caters to the growing need for diversity in clinical research. With an increasing focus from regulators and pharmaceutical companies on inclusive practices, Veeda stands to become one of the few CROs specializing in oncology, equipped with proprietary technology.
Enhancing Operational Efficiencies
This collaboration is part of Veeda’s broader objective to modernize its technological framework. The integration of the Querent™ platform will streamline clinical processes, improve data management procedures, and maintain rigorous quality standards. By ensuring broader representation in clinical trials, particularly among non-Caucasian populations, the partnership promises to enhance the overall efficiency of clinical trials through improved patient matching, trial designs, and monitoring capabilities.
Innovations in Real-World Evidence
Dr. Mohit Misra, the Founder and CEO of Mango Sciences, highlighted the significance of integrating Large Language Models (LLMs) and Generative-AI into their Querent™ platform. This evolution is expected to propel operational efficiencies and bolster real-world evidence, ultimately optimizing patient care by matching the right treatments with the right individuals.
Strengthening Veeda’s Competitive Edge
Veeda has established itself as a tech-enabled, AI-driven leader in the CRO space through strategic investments and acquisitions, including a notable partnership with Health Data Specialists. This has positioned Veeda to access oncology cohorts both in India and globally, thereby enabling it to maintain a competitive advantage while serving clients in the pharmaceutical and biopharmaceutical sectors. The aim is to continue delivering high-quality services that meet the rigorous standards expected in today's rapidly evolving healthcare landscape.
About Veeda Lifesciences
Veeda Lifesciences offers a broad array of services that span the drug development continuum, tailored to support the needs of small and medium biotech and pharmaceutical companies. Its capabilities range from non-clinical and pre-clinical development to eventual clinical pharmacology and trials encompassing various modalities.
About Mango Sciences
Mango Sciences prides itself on its commitment to transforming patient care through innovative data analytics solutions. Founded by experts with rich backgrounds in healthcare and life sciences, Mango Sciences aims to enhance patient representation and improve access to healthcare through advanced analytics.
Frequently Asked Questions
1. What is the focus of the partnership between Veeda and Mango Sciences?
The partnership aims to integrate AI technology into clinical trials, enhancing the efficiency and diversity of patient recruitment.
2. Who are the leaders involved in this partnership?
Dr. Mahesh Bhalgat leads Veeda Lifesciences, while Dr. Mohit Misra heads Mango Sciences, both contributing their expertise to this collaboration.
3. How will the Querent™ platform improve clinical trials?
The Querent™ platform will automate patient identification, enhance data management, and ensure greater diversity in patient representation.
4. Why is diversity important in clinical trials?
Diversity in clinical trials ensures that the results are applicable to a broader population, improving the overall quality and relevance of the research.
5. What are Veeda's capabilities in drug development?
Veeda offers comprehensive services across the drug development value chain, catering to various sectors in the biotech and pharmaceutical industries.
